The strategic reduction in AKT1 and BCL2 expression or phosphorylation, coupled with the amplification of TP53 expression and the consequent inhibition of pathway activation, delineates a promising therapeutic avenue against NPC, reinforcing the drug pair’s potential in cancer therapy. Here, BCL2 is linked to nasopharyngeal carcinoma.